Loading...
•
Dec 31, 2020
Enanta Pharmaceuticals Q1 2021 Earnings Report
Reported financial results for the first quarter of fiscal year 2021.
Key Takeaways
Enanta Pharmaceuticals reported a decrease in total revenue due to lower HCV product sales by AbbVie, resulting in a net loss for the quarter, while advancing its pipeline programs in HBV and RSV.
Royalty revenue for the quarter was $31.7 million.
Cash and marketable securities totaled $404.7 million at the end of the quarter.
Initiated RSVTx, a Phase 2b study of EDP-938 in adult hematopoietic cell transplant recipients with acute Respiratory Syncytial Virus (RSV) infection.
Broadened Hepatitis B Virus (HBV) Program with EDP-721, a New Oral HBV RNA Destabilizer, as a Potential Component of a Functional HBV Cure Regimen; Plan to Initiate Phase 1 Study Mid-2021.
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Enanta Pharmaceuticals Revenue by Segment
Revenue by Segment
Royalty Revenue
CapyFin.com Forward Guidance
Enanta expects to progress through numerous milestones across its entire pipeline in the upcoming year.